Clinical Trial Update: Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) [Phase 2]

View source ↗

Summary

A Phase 2 trial (VolATIL) evaluating UCPVax vaccine in combination with atezolizumab for HPV-positive cancers has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Canal Cancer
• Cervical Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Atezolizumab (atezolizumab)
• UCPVax

Snippet

Sponsor: Centre Hospitalier Universitaire de Besancon | Conditions: Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer | Phase 2 | Status: COMPLETED